Jump to content
  • image.png

    Rosacea is a chronic inflammation of the central face characterized by flare-ups, flushing, erythema, telangiectasia, lesions with papules/pustules and possible remission and relapse conditions. It has been conventionally defined by a certain age (generally adult onset) or period for its occurrence but as we have seen in many cases there is no typical age for its occurrence. It also has been correlated with certain ethnic background and skin types particularly fair skinned people but now it is found affecting people of all different backgrounds and skin of color people. In fact, diagnosis of rosacea is very challenging and difficult in skin of color. The underlying cause of rosacea includes aberrant immune system, environmental factors, genetics and most importantly microbial flora of our skin. Sometimes only one factor predominantly plays its part and sometimes all the factors play together to cause an inflammatory response in rosacea. It mostly affects women but sometimes causes very severe form in men in cases of rhinophyma. Rosacea is a condition which in some cases co-exists with other skin conditions and ocular manifestations and may present comorbidities with other parts of the body especially correlating with intestinal inflammation. There are further theories with this condition and more yet to explore which needs further investigation into rosacea research.

    More info on the definition of rosacea

    According to the classification based on phenotypical characteristics, we will explore the characteristic patterns of each phenotype going deeper into skin.

    Flushing in Rosacea [Phenotype 1] :

    image.png

    Flushing is usually but not always the earliest sign of rosacea which is marked by the redness of the skin with persistent episodes. Though the redness is caused by the dilation of the blood vessels beneath the skin, however, in its initial level, the early signs of flushing do not show the typical visible blood vessels appearing immediately. Flushing is characterized by a sudden feeling of warmth, tender, stinging, dry and itchiness of the skin. In this stage you can see your pores are very little enlarged contrasting to its natural state and are restored to its natural state when the flushing disappear. It depends on its frequency and comes and goes on its own but with physical responses such as stress and stress of their own flushing, anxiety, fear and other emotional states, it prolongs its time to disappear. Some people only show the flushing condition and never develop the other phenotypes of rosacea but for some people it is the onset and early sign of rosacea which furthers down to other phenotypes appearing at later stages. We will consider the other phenotypes later to delve into a deeper understanding of rosacea.

    You can read earlier post on phenotypes to know about characteristics and other information.

    Written and Illustrated by Apurva Tathe

  • Posts

    • "These findings demonstrate the broad‐spectrum antiviral property of ivermectin benefiting for COVID‐19 treatment in the context of predictive, preventive, and personalized medicine in virus‐related diseases." J Cell Physiol. 2020 Sep 22 : 10.1002/jcp.30055. doi: 10.1002/jcp.30055 [Epub ahead of print] Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment Na Li, Lingfeng Zhao,  Xianquan Zhan "Close to 70 clinical trials are currently in progress worldwide for SARS-CoV-2. Although few of these studies have been completed, the results that are available, as well as those from observational/retrospective studies, indicate clinical benefit. Here we discuss the case for ivermectin as a host-directed broad-spectrum antiviral agent, including for SARS-CoV-2." Biochem Biophys Res Commun. 2020 Oct 21 doi: 10.1016/j.bbrc.2020.10.042  The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2? David A. Jansa, Kylie M. Wagstaffb
    • Comments on "The Decrease of Demodex Density After Nd:YAG Laser Application for Facial Telengiactasias: A Case Report". Dermatol Ther. 2020 Oct 27;: Clatici VG, Voicu C, Barinova E, Tatu AL
    • Comments on "The Decrease of Demodex Density After Nd:YAG Laser Application for Facial Telengiactasias: A Case Report". Dermatol Ther. 2020 Oct 27;: Authors: Clatici VG, Voicu C, Barinova E, Tatu AL PMID: 33107672 [PubMed - as supplied by publisher] {url} = URL to article
    • The RRDi has been using Invision Community forum platform since 2004. When we started in 2004 it was recommended by Warren Stuart who was the assistant director of the RRDi to use what was then called Invision Power Services (later the name was changed to Invision Community). It is a powerful platform with many add-on features and a significant number of developers adding plugins and additional features to the platform. However, with the advent of mobile devices and social media platforms the trend has focused on mobile apps using iOS and Android devices found in the Apple App Store and Google Play Store. The popularity of using these apps over using a browser to view a website has increased the use of social media platforms such as Reddit, Facebook, Instagram, Twitter, etc. The developers and owners of the Invision Community platform have now announced beta versions of iOS and Android apps for their platform which has been embedded for years using only a web browser, so we have announced with this post here asking for volunteers to download the beta versions and help test these new apps. Please consider volunteering and using these beta versions of the apps.  Invision Community Clients There are some significant clients who use Invision Community as their platform which you can see below:  Medical Clients Who Use Invision Community Platform
    • Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide. Front Immunol. 2020;11:559589 Authors: Dondalska A, Rönnberg E, Ma H, Pålsson SA, Magnusdottir E, Gao T, Adam L, Lerner EA, Nilsson G, Lagerström M, Spetz AL Abstract Numerous inflammatory skin disorders display a high prevalence of itch. The Mas-related G protein coupled receptor X2 (MRGPRX2) has been shown to modulate itch by inducing non-IgE-mediated mast cell degranulation and the release of endogenous inducers of pruritus. Various substances collectively known as basic secretagogues, which include inflammatory peptides and certain drugs, can trigger MRGPRX2 and thereby induce pseudo-allergic reactions characterized by histamine and protease release as well as inflammation. Here, we investigated the capacity of an immunomodulatory single-stranded oligonucleotide (ssON) to modulate IgE-independent mast cell degranulation and, more specifically, its ability to inhibit the basic secretagogues compound 48/80 (C48/80)-and LL-37 in vitro and in vivo. We examined the effect of ssON on MRGPRX2 activation in vitro by measuring degranulation in a human mast cell line (LAD2) and calcium influx in MRGPRX2-transfected HEK293 cells. To determine the effect of ssON on itch, we performed behavioral studies in established mouse models and collected skin biopsies for histological analysis. Additionally, with the use of a rosacea mouse model and RT-qPCR, we investigated the effect on ssON on LL-37-induced inflammation. We reveal that both mast cell degranulation and calcium influx in MRGPRX2 transfected HEK293 cells, induced by the antimicrobial peptide LL-37 and the basic secretagogue C48/80, are effectively inhibited by ssON in a dose-dependent manner. Further, ssON demonstrates a capability to inhibit LL-37 and C48/80 activation in vivo in two mouse models. We show that intradermal injection of ssON in mice is able to block itch induced via C48/80 in a dose-dependent manner. Histological staining revealed that ssON inhibits acute mast cell degranulation in murine skin treated with C48/80. Lastly, we show that ssON treatment ameliorates LL-37-induced inflammation in a rosacea mouse model. Since there is a need for new therapeutics targeting non-IgE-mediated activation of mast cells, ssON could be used as a prospective drug candidate to resolve itch and inflammation in certain dermatoses. PMID: 33101278 [PubMed - in process] {url} = URL to article
×
×
  • Create New...